BRAF and melanoma: Increased TAMs and PD-L1 are associated with melanoma resistance to the single-agent BRAF (Serine/threonine-protein kinase B-raf) inhibitor dabrafenib or in combination with MEK (Mitogen-activated protein kinase) inhibitor trametinib [283].